Gossamer Bio, Inc. (GOSS)

Market Cap	87.96M -68.2%
Revenue (ttm)	48.47M -57.7%
Net Income	-170.37M
EPS	-0.75
Shares Out	234.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,563,040
Open	0.3744
Previous Close	0.3815
Day's Range	0.3637 - 0.4108
52-Week Range	0.3213 - 3.8700
Beta	2.11
Analysts	Buy
Price Target	4.19 (+1,017.93%)
Earnings Date	Mar 17, 2026

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS
• Website: https://www.gossamerbio.com

Financial Performance

In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.

Analyst Summary

According to 8 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price target is $4.19, which is an increase of 1,017.93% from the latest price.

Price Target

$4.19

(1,017.93% upside)

Analyst Consensus: Buy